Doxorubicin resistance in breast cancer is driven by light at night‐induced disruption of the circadian melatonin signal
暂无分享,去创建一个
Lin Yuan | Debasis Mondal | Tripp Frasch | S. Hill | Lin Yuan | L. Mao | T. Frasch | D. Mondal | V. Belancio | S. Xiang | D. Blask | Shulin Xiang | Robert T Dauchy | Adam Hauch | Lulu Mao | Melissa A Wren | Victoria P Belancio | David E Blask | Steven M Hill | R. Dauchy | Adam Hauch | Melissa A. Wren | Robert T. Dauchy | Melissa A. Wren | Victoria P. Belancio | David E. Blask
[1] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[2] B. Katzenellenbogen,et al. Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[3] E. Maser,et al. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. , 2008, Toxicology letters.
[4] T. Beerman,et al. DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. , 1991, Cancer communications.
[5] H. Burris,et al. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.
[6] F. Herrera,et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells , 2013, British Journal of Cancer.
[7] R. Mamillapalli,et al. Switching of G-protein Usage by the Calcium-sensing Receptor Reverses Its Effect on Parathyroid Hormone-related Protein Secretion in Normal Versus Malignant Breast Cells* , 2008, Journal of Biological Chemistry.
[8] M. Zabel,et al. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. , 2002, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[9] Josephine Arendt,et al. Melatonin and Human Rhythms , 2006, Chronobiology international.
[10] K. Huse,et al. Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver , 2008, Drug Metabolism and Disposition.
[11] Yunpeng Liu,et al. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. , 2014, Oncology reports.
[12] B. Fang. Genetic Interactions of STAT3 and Anticancer Drug Development , 2014, Cancers.
[13] Zhiming He,et al. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. , 2011, Acta biochimica et biophysica Sinica.
[14] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Plattner,et al. Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1 , 2013, PloS one.
[16] Lin Yuan,et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. , 2014, Cancer research.
[17] M. Dubocovich,et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. , 2005, Cancer research.
[18] P. Singal,et al. Adriamycin cardiomyopathy: pathophysiology and prevention , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] N. Sarvazyan,et al. Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. , 1995, Life sciences.
[20] E. D. Bal de Kier Joffé,et al. Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs , 2011, Breast Cancer Research and Treatment.
[21] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[22] G. Hortobagyi,et al. Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.
[23] A. Jubb,et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. , 2012, Cancer research.
[24] Michael W. Greene,et al. Light Exposure at Night Disrupts Host/Cancer Circadian Regulatory Dynamics: Impact on the Warburg Effect, Lipid Signaling and Tumor Growth Prevention , 2014, PloS one.
[25] V. Adam,et al. A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin , 2013, International journal of molecular sciences.
[26] L. Hlatky,et al. Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart , 2012, Front. Pharmacol..
[27] D. Gewirtz,et al. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.
[28] P. Ang,et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients , 2008, Cancer science.
[29] R. Reiter,et al. Pharmacological actions of melatonin in oxygen radical pathophysiology. , 1997, Life sciences.
[30] H. Ahmed,et al. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. , 2005, Bioorganic & medicinal chemistry.
[31] F. Baltazar,et al. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin , 2013, Journal of Bioenergetics and Biomembranes.
[32] S. Hill,et al. Melatonin and Associated Signaling Pathways that Control Normal Breast Epithelium and Breast Cancer , 2011, Journal of Mammary Gland Biology and Neoplasia.
[33] J. Schellens,et al. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma , 2005, Cancer Chemotherapy and Pharmacology.
[34] R. Olson,et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[35] P. Singal,et al. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. , 1991, The American journal of physiology.
[36] W. Glasgow,et al. Modulation of epidermal growth factor signal transduction by linoleic acid metabolites. , 1997, Advances in experimental medicine and biology.
[37] L. Nabell,et al. Chemotherapy-Resistant Metastatic Breast Cancer , 2012, Current Treatment Options in Oncology.
[38] Philippe P Roux,et al. Regulation and function of the RSK family of protein kinases. , 2012, The Biochemical journal.
[39] P. Ang,et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients , 2008, Cancer science.
[40] J. Karaszkiewicz,et al. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. , 1992, Cancer research.
[41] Bonnie F. Sloane,et al. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. , 2008, Neoplasia.
[42] P. Lønning,et al. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy , 2014, Expert opinion on pharmacotherapy.
[43] E. Monti,et al. Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. , 2003, International journal of oncology.
[44] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[45] Arnima Bhasin,et al. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. , 2013, Cancer research.
[46] R. Roskoski. The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.
[47] Y. Gotoh,et al. Scaffolding function of PAK in the PDK1–Akt pathway , 2008, Nature Cell Biology.
[48] Hara,et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. , 1995, Biochemical pharmacology.
[49] Ming-cheng Lin,et al. Preventive Effects of Ellagic Acid Against Doxorubicin-Induced Cardio-Toxicity in Mice , 2013, Cardiovascular Toxicology.